Holland & Knight and Mondaq Legal Analyses Published Following the July 23-24 FDA Pharmacy Compounding Advisory Committee (PCAC) Vote Clarify the Rulemaking Process for the Six Recommended Peptides (BPC-157, KPV, TB-500, MOTS-c, Semax, Epitalon): HHS Secretary Robert F. Kennedy Jr. Must Formally Approve the Substances for 503A Bulks List Inclusion, and No Compounding Is Permitted Until Final Rulemaking Completes (Typically 12-24 Months From Advisory-Committee Recommendation); The FDA Has Announced a Second PCAC Peptide Meeting Before the End of February 2027 to Review Five Additional Peptides (Cathelicidin/LL-37, GHK-Cu, Dihexa Acetate, Melanotan II, PEG-MGF)
Holland & Knight and Mondaq legal analyses published following the July 23-24, 2026 FDA Pharmacy Compounding Advisory Committee (PCAC) vote clarify the rulemaking process for the six recommended peptides (BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon; Emideltide/DSIP rejected). Key legal clarifications: PCAC recommendations are advisory only; HHS Secretary Robert F. Kennedy Jr. must formally approve the substances for Section 503A Bulks List inclusion; no compounding pharmacy is permitted to legally compound the peptides until final rulemaking completes; formal rulemaking typically takes 12-24 months from advisory-committee recommendation (Notice of Proposed Rulemaking, public comment period, response to comments, final rule with effective date). Even after final rule takes effect, individual states retain authority under state pharmacy board oversight to further restrict or condition compounded-peptide preparation. Separately, the FDA has announced a second PCAC peptide meeting before the end of February 2027 to review five additional peptides: cathelicidin (LL-37, antimicrobial peptide), GHK-Cu (copper tripeptide cosmetic peptide), dihexa acetate (nootropic), melanotan II (α-MSH analog), and pegylated mechano growth factor (PEG-MGF, muscle repair). Combined, the July 2026 and February 2027 PCAC dockets bring 12 peptides through advisory-committee review as part of the broader Trump administration and HHS Secretary RFK Jr. peptide deregulation agenda that has moved through the regulatory system since Q1 2026.